



QM 1: Pre-Treatment Workup: Brain MRI or CT, AND PET-CT




QM 2: Assessment of Histological or Cytological Type




QM 3: Squamous or Non-squamous NSCLC Documentation*

*SCLC patients are excluded from this QM. They are not evaluated.




QM 4: Collection of Molecular Information*


*SCLC patients are excluded from this QM. They are not evaluated.




QM 5: Clinical Stage




QM 6: Multidisciplinary Consult




QM 7: Performance Status




QM 8A: Smoking Status




QM 8B: Smoking Cessation Referral/Counseling




QM 9: Enrolled Clinical Trial



QM 10: Implantable Cardiac Device



QM 11: Use of 3D or IMRT



The QM will be evaluated with all planning types on a Pass/Fail level, while the percentage of IMRT/3D plans will be a secondary evaluation

Secondary Analysis


Collect:

Total # of IMRT Plans per Site


Total # of 3D Plans per Site

Secondary analysis data should be presented as a percentage of plans that utilized IMRT out of all the IMRT and 3D plans per site


QM 12: Contouring of OARs




QM 13: Heterogeneity Planning Algorithm




QM 14: Motion Management




QM 15: 28 Days from Diagnosis to First Treatment




QM 16: 21 Days from Consult to First Radiation Treatment




QM 17: 14 Days from Simulation to First Treatment



QM 18: Concurrent Chemo and Radiation Therapy



QM 19: Appropriate Dose for NSCLC




Exclusions	Fails	Pass
On a Clinical Trial	Dose prescription for EBRT plans combined less than 59 Gy	Chemo/EBRT Patients with a Total EBRT perscription more than 59 Gy and less than 70 Gy that also have a Dose/Fx between 180-200 cGy/Fx per EBRT plan
Any plans with fractionation outside of 180-200 cGy/Fx Including SBRT	Dose prescription for Chemo/EBRT plans combined less than 59 Gy or more than 70 Gy	EBRT only Patients with a Total EBRT perscription more than 59 Gy that also have a Dose/Fx between 180-200 cGy/Fx per EBRT plan Within this criteria there is also a color scale: Green: 59Gy ≤Dose≤ 74 Gy Yellow:74 Gy <Dose≤ 84 Gy Red: 84 Gy < Dose

NSCLC Patients Only

Minor Changes
may still be coming
to this metric
(more specifically a
color grading like
NSCLC)

QM 20: Appropriate Dose for SCLC


Exclusions	Fails	Pass
On a Clinical Trial	Dose prescription for EBRT plans combined less than 59 Gy	BID Patients with a Total EBRT prescription more than 40.5 Gy that also have a Dose/Fx is 150 cGy/Fx per EBRT phase
Any plans with fractionation outside of 180-200 cGy/Fx Including SBRT	Dose prescription for Chemo/EBRT plans combined less than 59 Gy or more than 70 Gy	QID Patients with <i>EITHER</i> 1. a Total EBRT prescription more than 36.045 Gy and less than 44.005 that also have a 15 total Fxs OR 2. a Total EBRT prescription more than 48.6 Gy and less than 77 Gy that also have a Dose/Fx between 180 and 200Gy per EBRT phase



Add a $\pm 10\%$
compliance to dose
constraints.


SCLC Patients Only

QM 21A: PCI for SCLC




QM 21B: Appropriate Dose for PCI


SCLC Patients Only




QM 22: Quality of Life Assessment Prior to Treatment Completion




QM 23: Survivorship Care Plan



QM 24: Follow-up Intervals (NSCLC)



QM 24: Follow-up Intervals (SCLC)



Evaluation 1: [QM] Toxicity Affirmation - Lung

- Calculate using the numerator/denominator below to calculate and report per:
 - Patient
 - Institution

$$1 - \frac{\text{\# of OTV and Follow-up notes w/ *Toxicity* not initialized}}{\text{total number of OTV and Follow-up notes}}$$

Evaluation 2: [QM] Toxicity Grading Rate – Lung Esophagitis

- Calculate toxicity timeframe to establish the applicable notes (OTV and Follow-up notes)
 - **Esophagitis Timeframe**: Toxicity with date \leq (treatment end date + 90 days)
- Then use the numerator/denominator below to calculate and report per:
 - Patient
 - Institution

# of toxicities of the dropdown menu toxicity "Type" mapped to Esophagitis with "Grade"	<div>Grade 1</div> <div>Grade 2</div> <div>Grade 3</div> <div>Grade 4</div> <div>Grade 5</div>
# of toxicities of the dropdown menu toxicity "Type" mapped to Esophagitis with "Grade"	<div>Grade 1</div> <div>Grade 2</div> <div>Grade 3</div> <div>Grade 4</div> <div>Grade 5</div> <div>Not Stated</div>

Evaluation 2: [QM] Toxicity Grading Rate – Lung Pneumonitis

- Calculate toxicity timeframe to establish the applicable notes (OTV and Follow-up notes)
 - **Pneumonitis Timeframe**: Toxicity with date \leq (treatment start date + 12 months)
- Then use the numerator/denominator below to calculate and report per:
 - Patient
 - Institution

# of toxicities of the dropdown menu toxicity "Type" mapped to Pneumonitis with "Grade"	<div>Grade 1</div> <div>Grade 2</div> <div>Grade 3</div> <div>Grade 4</div> <div>Grade 5</div>
# of toxicities of the dropdown menu toxicity "Type" mapped to Pneumonitis with "Grade"	<div>Grade 1</div> <div>Grade 2</div> <div>Grade 3</div> <div>Grade 4</div> <div>Grade 5</div> <div>Not Stated</div>

QM 27: Grade 4 OR 5 Toxicity Discussed at M&M

